Medroxyprogesterone therapy for sexual precocity in girls
P. A. Lee
An evaluation of 13 girls who had been treated intramuscularly with
medroxyprogesterone acetate for sexual precocity showed that this drug has
no effect on growth, skeletal maturation, or adult height. During treatment
(mean duration, 3.6 years), menstruation was suppressed and breast size
initially regressed, but breast development and public hair development
progressed during long-term therapy. The extent of delay in resumption of
menses after cessation of therapy was related both to duration of treatment
and dosage of the drug.
